Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.95 |
| ▸ | CA1 | P00915 | 5/20 | 0.95 |
| ▸ | CA2 | P00918 | 5/20 | 0.95 |
| ▸ | CA7 | P43166 | 5/20 | 0.95 |
| ▸ | CA9 | Q16790 | 5/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.95 |
| ▸ | CA4 | P22748 | 3/20 | 0.95 |
| ▸ | CA6 | P23280 | 3/20 | 0.95 |
| ▸ | MAPT | P10636 | 2/20 | 0.95 |
| ▸ | GAA | P10253 | 2/20 | 0.95 |
| ▸ | POLB | P06746 | 1/20 | 0.95 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.95 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.95 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | CA5A | P35218 | 2/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protocatechuic Acid SCHEMBL29005616 | 1.00 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL39435 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL30030432 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL27815804 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL29350008 | 0.97 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL23495982 | 0.95 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL2274950 | 0.95 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL30767247 | 0.95 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL30677996 | 0.95 | CA12 (0.95) | CA12CA1CA2CA7CA9 | |
| Protocatechuic Acid SCHEMBL28487427 | 0.95 | CA12 (0.95) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4118079-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | Novartis AG (CH) | 2023-01-18 | — | — | EP | claimed |
| CN-115279745-A | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same | 诺华股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114672068-A | Intumescent flame retardant for polyurethane, flame-retardant polyurethane and preparation of flame-retardant polyurethane | 四川大学 | 2022-06-28 | — | — | CN | claimed |
| WO-2021181361-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS AG (CH) | 2021-09-16 | — | — | WO | claimed |
| CN-113387923-A | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same | 诺华股份有限公司 | 2021-09-14 | — | — | CN | claimed |
| CN-118099430-A | Cathode for secondary battery and cathode slurry | 广东省皓智科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-114424365-B | Cathode for secondary battery and cathode slurry | 广东省皓智科技有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-116019125-B | Chlorine dioxide slow-release gel and preparation method thereof | 山东华实药业有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116019125-A | Chlorine dioxide slow-release gel and preparation method thereof | 山东华实药业有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11590158-B2 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | NOVARTIS AG (CH) | 2023-02-28 | — | — | US | disclosed |
| EP-4118079-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | Novartis AG (CH) | 2023-01-18 | — | — | EP | disclosed |
| CN-115279745-A | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same | 诺华股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114424365-A | Cathode for secondary battery and cathode slurry | 广东省皓智科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210393671-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS PHARMA AG (CH) | 2021-12-23 | — | — | US | disclosed |
| US-11135239-B1 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | NOVARTIS AG (CH) | 2021-10-05 | — | — | US | disclosed |
| WO-2021181361-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS AG (CH) | 2021-09-16 | — | — | WO | disclosed |
| US-20210283171-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | NOVARTIS PHARMA AG (CH) | 2021-09-16 | — | — | US | disclosed |
| CN-113387923-A | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using the same | 诺华股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-5189157-A | ANTIBACTERIAL CEPHALOSPORIN COMPOUNDS | HOFFMANN LA ROCHE INC. (US) | 1993-02-23 | — | — | US | disclosed |
| US-5145946-A | PROCESS FOR PREPARING POLYARYLENE SULFIDE WITH ALKALI METAL SALT OF PHENOLIC AROMATIC CARBOXYLIC ACID | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393671-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | LIPA, LIPC, LIPE | CA12 222/4885CA1 270/4885CA2 260/4885 |
| US-11135239-B1 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | LIPA, LIPC, LIPE | CA12 222/4885CA1 270/4885CA2 260/4885 |
| US-11590158-B2 | Pharmaceutical compositions of lipoic acid choline ester salts and methods of treatment using same | LIPA, LIPC, LIPE | CA12 222/4885CA1 270/4885CA2 260/4885 |
| US-20210283171-A1 | PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME | LIPA, LIPC, LIPE | CA12 222/4885CA1 270/4885CA2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.